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Abstract  
Background. Patients with acute and transient psychotic disorders (ATPDs) are by definition remitting, but 
have a high risk of developing persistent psychoses, resembling a subgroup of individuals at Clinical High 
Risk for Psychosis (CHR-P). Their pathways to care, treatment offered and long-term clinical outcomes 
beyond risk to psychosis are unexplored. We conducted an electronic health record-based retrospective cohort 
study including patients with ATPDs within the SLaM NHS Trust and followed-up to 8 years. 
Methods. A total of 2561 ATPDs were included in the study. A minority were detected (8%) and treated (18%) 
by Early Intervention services (EIS) and none by CHR-P services. Patients were offered a clinical follow-up 
of 350.40589.90 days. The cumulative incidence of discharges was 40% at 3 months, 60% at 1 year, 69% at 
2 years, 77% at 4 years, and 82% at 8 years. Treatment was heterogeneous: the majority of patients received 
antipsychotics (up to 52%), only a tiny minority psychotherapy (up to 8%).  
Results. Over follow-up, 32.88% and 28.54% of ATPDS received at least one mental health hospitalization or 
one compulsory hospital admission under the Mental Health Act, respectively. The mean number of days spent 
in psychiatric hospital was 66.39239.44 days.  
Conclusions. The majority of ATPDs are not detected/treated by EIS or CHR-P services, receive 
heterogeneous treatments and short-term clinical follow-up. ATPDs have a high risk of developing severe 
clinical outcomes beyond persistent psychotic disorders and unmet clinical needs that are not targeted by 
current mental health services.  
 
Keywords: Psychosis, Schizophrenia, Risk, Prevention, ATPDs 
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1. Introduction 
Short-lived psychotic episodes are traditionally classified as Brief Psychotic Disorders (BPD, in DSM-V) and 
Acute and Transient Psychotic Disorders (ATPDs in ICD-10), respectively1. Recently, patients presenting with 
short-lived psychotic episodes have been included in the Brief Limited Intermittent Psychotic Symptoms 
(BLIPS) or Brief and Intermittent Psychotic Symptoms (BIPS) subgroups of the Clinical High Risk state for 
Psychosis (CHR-P)2,3 . There is a diagnostic overlap (70%) between BLIPS and ATPDs4. Whichever the 
designation used, patients with short-lived psychotic episodes share: (i) psychotic symptoms with a brief 
duration from 7 days (BLIPS) to 3 months (ATPDs) 4, and (ii) a very high risk of developing persistent 
psychotic disorders. This risk accumulates to 0.51 [0.41-0.61] at 3-years5. Specifically, one-fourth of patients 
with an initial ATPDs diagnosis would develop schizophrenia-spectrum psychoses and up to one-third  
affective psychoses6. However, although about one in two ATPDs patients will develop persistent psychotic 
disorders at follow-up, their risk is lower than the risk observed in patients with an initial first-episode of 
schizophrenia who remitted from their symptoms5.  
There is limited knowledge with respect to ATPDs’: (i) pathways to care (i.e., which clinical services detect, 
treat and follow-up these patients), (ii) treatment offered and (iii) long-term outcomes beyond the risk of 
developing persistent psychotic disorders in clinical practice. The paucity of research in this area may reflect 
the fact that these patients are by definition remitted at the time of their index diagnosis and therefore their 
perceived need of care may be low, an assumption largely unverified. For example, in the UK the National 
Health Service (NHS) Mental Health Trusts assume that Early Intervention Services (EIS) for psychosis and 
CHR-P services are the deputy services to take care of these individuals, under the ATPDs or BLIPS/BIPS 
designations, respectively7. Yet, it is undetermined how many ATPDs are actually detected and treated by EIS 
or CHR-P services in the real-world clinical routine. Furthermore, under current guidelines, patients presenting 
with a short-lived psychotic episode may either be recommended conventional antipsychotic treatment (if 
diagnosed with ATPDs and according to the current EIS guidelines)8 or be contraindicated antipsychotic 
treatment and receive psychological therapies (if diagnosed with BLIPS by CHR-P services)8.  Yet, the actual 
type of care which is offered to these patients is unknown. For example, it is undetermined how many ATPDs 
patients would actually undergo antipsychotic treatment or whether they would undergo any other types of 
treatment such as psychotherapy or clinical monitoring. Further, mental health outcomes other than the risk to 
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develop a persistent psychotic disorder, such as number of admissions in mental health hospitals, days spent 
in hospital, and use of Mental Health Act (MHA) assessment in this population are unknown.  
Overall, the lack of knowledge about the real-world needs of these patients puts them in a position of increased 
risk of receiving inappropriate interventions. It is thus essential to gain new knowledge into their pathways to 
care, treatment offered and broader long-term health outcomes. This study aims at overcoming such a gap in 
knowledge by describing (i) the pathways to care, (ii) the treatment received and (iii) the long-term health 
outcomes other than risk to develop any persistent psychoses in a large cohort of ATPDs cases.  
 
2. Methods  
2.1 Data source 
Data for this study were extracted from the South London and Maudsley (SLaM-BRC) Case Register, using 
the Clinical Record Interactive Search tool (CRIS) 9. SLaM is a large NHS Trust providing specialist mental 
health care to an area of 1.3 million residents across London9. Every patient within SLaM has their electronic 
health record, which is continually updated by SLaM health-care professionals as a legal requirement9. CRIS 
was approved by the Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). CRIS has been 
used in over 70 previous studies 10–12 
 
2.2 Study population 
Individuals with an index primary diagnosis of ATPDs (F23, ICD-10) within SLaM between 1st April 2006 
and 15th June 2017 were initially considered eligible 9. To make the diagnoses more robust, we excluded those 
who developed a psychotic disorder other than ATPDs within the 3 months immediately following the first 
index diagnosis (i.e., in the context of the index episode itself)13.  
 
2.3 Follow-up  
Follow-up started at the time of the index diagnosis of ATPDs. The end of follow-up was then placed at several 
a-priori cutoffs ranging from 1 month to 8 years, as indicated below. In the case of time-dependent outcomes 
(see statistical analysis), censoring occurred on 15th June 2017 or at the time of the event of interest.  
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2.4 Study outcomes 
The primary outcome was to describe: (i) the pathways to care, (ii) the treatment received, and (iii) the long-
term outcomes of individuals with ATPDs other than risk to develop a persistent psychotic disorder.  
 
(i) Pathways to care. Patients’ pathways to care within SLaM follows three steps. The first step is acceptance 
within SLaM. Patients are assigned to a SLaM team that proceeds with their assessment and evaluates if the 
service is appropriate for their clinical needs. These are the teams that detect the patients - we will refer to 
these teams as Assessment team. The second step is diagnosis and treatment. These can be operated by the 
same team that accepted the patients within SLaM, or by another team (if it is thought that the assessment team 
was not appropriate for patients’ clinical needs). We will refer to the team that makes the definitive diagnosis, 
delivers the treatment and offers clinical follow-up as the Treatment team.  
SLaM teams were categorized as follows: Accident and Emergency (Liaison Psychiatry), Child and 
Adolescent Mental Health, Early Intervention in Psychosis, Forensic Mental Health, Adult Community Mental 
Health, Older Adults Mental Health, Physical Health (Liaison Psychiatry), Psychosis Community, Substance 
abuse and CHR-P services. Given that the Early Intervention Services (EIS) are the deputed services for 
treatment of ATPDs (and CHR-P services for the similar BLIP designation), we considered them as reference 
treatment services for comparative analysis. 
The third step is discharge by the SLaM treatment team. On the basis of the above considerations, we described 
the pathways to care with three outcome variables:  
1) The type of SLaM service that detect (Assessment team), diagnose, offer treatment and clinical follow-up 
(Treatment team) to patients. 
2) Duration of clinical follow-up offered by Treatment teams. 
3) The cumulative incidence of discharges by Treatment teams and time to discharge (time-dependent 
outcome). 
 
(ii) Treatment  
1) Exposure to antipsychotics, antidepressants, or psychotherapy at 1 month, 3 months, 6 months, 1 year, 2 
years, 4 years, 6 years, and 8 years. 
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2) Cumulative incidence of first antipsychotic prescription and time to first antipsychotic prescription (time-
dependent outcome). 
 
(iii) Long term health outcomes other than risk to develop persistent psychoses.  
1) The percentage of mental health hospitalizations and compulsory hospital admissions (MHA) at 1 month, 
3 months, 6 months, 1 year, 2 years, 4 years, 6 years, and 8 years.  
2) The percentage of ATPDs that received at least one mental health hospitalization or one compulsory 
hospital admission (MHA) at 8 years of follow-up. 
3) The overall number of days spent in mental health hospitals at 8 years.  
 
Age and ATPDs subtypes might have an impact on pathways to care and long-term health 
outcomes, respectively.  For this reason, additional analyses were conducted to provide data on age-
based differences in pathways to care and on ATPDs subtypes differences in long-term health 
outcomes (see Supplementary material - eResults) 
 
2.5 Statistical analysis  
This electronic health record-based cohort study was performed according to the REporting of Studies 
Conducted using Observational Routinely-collected health Data statement (RECORD)14 (eTable1). 
We described sociodemographic and clinical characteristics of the sample by mean and standard deviation 
(SD) for continuous variables, and by absolute and relative frequencies for categorical variables.  
Pathways to care was measured as: the percentage of ATPDs detected by Assessment teams and treated by 
Treatment teams; the duration of clinical follow-up measured as mean length of care (days) under a Treatment 
team; the cumulative incidence of discharges from Treatment teams and time to discharge, estimated with 
Kaplan-Meier failure analysis and Greenwood 95% confidence intervals15 . Supplementary analyses 
investigated the differential impact of EIS vs other types of SLaM services on these outcomes.  
Treatment was measured as the percentage of ATPDs treated with any antipsychotics (yes/no), antidepressants 
(yes/no), psychotherapy (yes/no) at 1 month, 3 months, 6 months, 1 year, 2 years, 4 years, 6 years, and 8 years. 
Supplementary descriptive analyses report the detail of the specific antipsychotic medications prescribed at 
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these time points. Treatment was further measured as the cumulative incidence of first antipsychotic 
prescription and time to first antipsychotic, estimated with Kaplan-Meier failure analysis and Greenwood 95% 
confidence intervals15. 
Long term health outcomes other than risk to develop persistent psychoses was measured as the percentage of 
mental health hospitalizations and compulsory hospital admissions (MHA) at 1 month, 3 months, 6 months, 1 
year, 2 years, 4 years, 6 years, 8 years. We also estimated the percentage of ATPDs that received at least one 
mental health hospitalization and one compulsory hospital admissions (MHA) over 8 years of follow-up. 
Finally, we reported the overall number of days spent in mental health hospitals over 8 years of follow-up.  
Data were analyzed using STATA 13 (STATA Corp., TX, USA). 
 
3. Results 
3.1 Sample characteristics 
Between 1st April 2006 and 15th June 2017, a total of 3286 subjects received a first index diagnosis of ATPDs 
(F23, ICD-10) within the SLaM NHS Trust. After 3 months, 2561 subjects had retained the index ATPDs 
diagnosis and were therefore included in the current study. The mean age of the sample at the index episode 
was 33.5818.86 (range: 5-92) and the male to female ratio 1.08; black and white ethnicities were the most 
represented (36.11% and 38.21%, respectively). The most frequent ATPDs subtypes were F23.8/F23.9 
(Other/Unspecified Acute Transient Psychotic Disorder). See also Table 1. The mean follow-up time was 
6.153.18 years (range 0-11). In the current manuscript, point estimates of time-dependent outcomes were 
reported up to 8-years, when at least 133 individuals were still at risk. 
 
*Table 1 about here* 
 
3.2 Pathways to care 
Almost half (47.52%) of the individuals with an index diagnosis of ATPDs accessing SLaM (Assessment 
teams) were detected by general mental health psychiatric services (Adult Community Mental Health Services 
– 36.46% and Older Adults Mental health – 11.06%). Only 8.15% of ATPDs were detected by EIS and none 
by CHR-P services (see Figure 1a). Diagnosis, treatment and clinical follow-up within SLaM (Treatment 
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teams) were mostly delivered by general mental health services (54.45%); only 18.02% were treated with EIS 
and no patients were treated by CHR-P services (see Figure 1b). The low prevalence of EIS in the assessment 
and treatment phases of ATPDs did not vary across different age-ranges (see Supplementary material -
eResults) 
Patients treated with EIS were significantly younger (EIS: 25.105.47 vs Others: 35.9414; t=14.04; p<0.01), 
more frequently males (EIS: 64.30% vs Others: 48.99%, 2=29.33; p<0.01), and black (EIS: 46.45% vs Others: 
35.76, 2=27.72; p<0.01).  
The average clinical follow-up duration provided by Treatment teams was 350.40589.90 days. The 
cumulative incidence of discharge from Treatment teams was 40.94% at 3 months (95%CI 38.86-43.09%), 
49.61% at 6 months (95%CI 47.48-51.78%%), 60.48% at 1 year (95%CI 58.39-62.59%), 69.13% at 2 years 
(95%CI 67.12-71.12%), 76.92% at 4 years (95%CI 75.03-78.76%), 80.40% at 6 years (95%CI 78.55-82.19%), 
81.59% at 8 years (95%CI 79.70-83.39%) (see eFigure1). Supplementary analyses reported in eFigure 2 
indicate that patients under the EIS have a longer clinical follow-up and are less likely to be discharged within 
the 4 years of follow-up.  
 
3.3 Treatment  
Figure 2 describes treatments received by ATPDs patients over time. The cumulative incidence of first 
antipsychotic prescription was 57.77% at 3 months (95% CI 55.86-59.69%); 63.88% at 6 months (95% CI 
62.02-65.74); 68.95% at 1 year (95% CI 67.15-70.74%); 70.71 at 2 years (95% CI 68.93-72.48); 73.98% at 4 
years (95% CI 71.61-75.12%); 74.44% at 6 years (95% CI 72.62-76.18%); 75.69% at 8 years (95% CI 73.86-
77.48%) (see eFigure3). Time to first antipsychotic medication was 120.55327.94 
In eFigure4 we reported the specific antipsychotic medication prescribed at the time points of interest, 
indicating that olanzapine is the most frequently prescribed antipsychotic.  
 
3.4 Long-term health outcomes  
The percentage of ATPDs that received at least one mental health hospitalization and one compulsory mental 
admission (MHA) over 8 years of follow-up were 32.88% and 28.54%, respectively (Figure 3). 
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The mean duration of mental health hospitalization within SLaM was 66.39239.44 days. Long-term health 
outcomes did not largely differ between different ATPDs subtypes (see Supplementary material - eResults) 
 
 
4. Discussion 
To the best of our knowledge this is the first study reporting on pathways to care, treatment, and long-term 
health outcomes other than transition to persistent psychotic disorders in a large sample of individuals with 
ATPDs. The study was conducted using an electronic case register that reflects the day-to-day clinical practice 
of a NHS Mental Health Trust in the UK and, as such, it has high ecological validity. We found that in clinical 
practice, the majority of ATPDs were not detected or treated by EIS or CHR-P services, received 
heterogeneous treatments and only short-term clinical follow-up. A substantial proportion of ATPDs would 
develop severe clinical outcomes beyond persistent psychotic disorders. These patients have unmet clinical 
needs that are not targeted by current mental health services. 
 
The first outcome of this study was pathway to care for ATPDs patients. Only a minority of patients were 
detected (8.15%) and treated (18.02%) by EIS, the deputed team for first-episode cases and therefore for taking 
care of ATPDs. Similarly, there were no ATPDs detected by CHR-P services. It can be argued that since CHR-
P services use a different designation (i.e. BLIPS) 4 these individuals were not retrieved in the current database. 
Thus, we checked in the data acquired from the local CHR-P service in the same period and catchment area of 
the current study (the Outreach and Support In South London)16, and found that only 49 BLIPS had been 
detected16,17. Assuming that about two-third of BLIPS (i.e. n=34) would meet ATPDs criteria4, the final 
proportion of ATPDs-like cases detected by CHR-P services is still negligible. Overall, only 241 (207 EIS + 
34 CHR-P) individuals with short-lived psychotic episodes have been detected out of the 2610 (2561 ATPDs 
+ 49 BLIPS) by the deputed mental health services (EIS or CHR-P), accounting for about 9% of cases. This is 
likely due to the fact that most ATPDs are too severe for CHR-P services; in fact, the duration of their episode 
(3 months) can extend that required to meet the BLIPS designation (7 days)5. At the same time, referrers in the 
community may be reluctant to refer ATPDs to EIS because their symptoms are remitted at the time of the 
diagnosis. Similarly, EIS may not be keen to accept first episode cases that are not severe enough to present 
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with persistent and disabling symptoms that resemble a first episode of schizophrenia spectrum psychoses. 
Thus, these patients will end up being referred to and treated with non-specialist community mental health 
services. In line with this speculation, ATPDs patients detected by EIS were typically younger, more frequently 
males and of black ethnicity, sociodemographic features that characterize non-affective psychoses18,19. As a 
result of the detection failure of the deputy teams (EIS and CHR-P), the large majority of ATPDs patients -
almost half- were indeed detected by general psychiatry services. These teams are not specialized in taking 
care of patients with a first episode of psychosis. Such a suboptimal detection inevitably leads to inefficient 
treatments. In fact, ATPDs patients received only a very short clinical follow-up: on average one year, with 
half of them being discharged from the initial teams after six months. Meta-analytical evidence clearly 
indicates that clinical follow-up in this group should be offered for at least 4 years, due to ATPDs’ risk of 
developing persistent psychotic disorders, which increases from 30% at 1 year to 54% at more than 3 years5. 
In line with these arguments, our supplementary analyses found that EIS teams, who have more clinical 
expertise in taking care of first-episode psychosis, were offering a longer clinical follow-up (about 1 year 
longer on average) than standard teams. EIS were also less likely to discharge ATPDs patients in the shorter 
term: within the first three months only a minority (21.15%) of ATPDs patients were discharged by EIS teams, 
compared to more than half (60.11%) of those treated by other teams (see eFigure2).  
 
Our second outcome was treatment received by ATPDs patients. In the context of short-term clinical follow-
up and early discharge from clinical teams, only 18.02% of ATPDs were treated by EIS. As such, the type of 
treatment offered by general mental health teams was not specific and quite heterogeneous, with olanzapine 
being the most frequently prescribed antipsychotic. Although ATPDs are self-remitting, almost everyone 
received antipsychotics over the follow-up period and one in ten were prescribed antidepressants. The use of 
antipsychotics in ATPDs is relatively under-reported, with only a few randomized trials that have investigated 
conventional antipsychotic treatment, the recommended treatment for a first episode of psychosis20–22. The 
consequent lack of precise therapeutic guidelines might explain why treatment received by ATPDs in the 
current study was not specific and heterogeneous. Interestingly, only a tiny minority of patients received 
psychotherapy interventions (less than 4% within the first 3 months). This may both indicate that 
psychotherapy is not offered by clinicians or accepted by patients, or is not available in the general psychiatry 
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teams where the majority of patients were treated. In the context of CHR-P services, we have observed that 
BLIPS patients are less likely to accept psychological therapies and have high drop-out rates from these.  
 
As recently highlighted by our research group, one-fourth of patients with an initial ATPDs diagnosis would 
develop schizophrenia-spectrum psychoses and up to one-third  affective psychoses23. Our third aim was 
therefore to investigate long-term outcomes other than risk to develop a persistent psychotic disorder. 32.88% 
and 28.54% of ATPDs received at least one mental health hospitalization or a compulsory hospital admission 
(MHA) over the 8 years of follow-up, respectively. A substantial proportion considering that this group is 
traditionally perceived to have a good prognosis and to not require long-term care or follow-up. For those 
ATPDs who were hospitalised, inpatient admission was not short and lasted on average about 2 months. 
Considering that half of patients with an ATPDs index diagnosis ultimately developed a persistent psychotic 
disorder over follow-up5,24, these results clearly indicate that ATPDs patients are at increased risk of serious 
long-term outcomes. The high long-term clinical needs of ATPDs contrasts with the relatively short clinical 
follow-up, high discharge rates and heterogeneous treatments observed in this group, confirming that these 
patients currently present with unmet needs that are not targeted by existing mental health services.  
 
Improving the care for ATPDs patients starts -as a first step- from a more efficient detection by specialized 
services which can offer them appropriate longitudinal follow-up and care. The BLIPS designation has been 
introduced specifically to facilitate an early detection of patients with short-lived psychotic episodes and their 
longitudinal care25, including prevention of poor long-term outcomes26. However, on the ground, the BLIPS 
approach has failed, because it has demonstrated no pragmatic utility to detect individuals with short-lived 
psychotic episodes in the real-world clinical scenarios. Clinicians working in the NHS prefer using the ATPDs 
designation when dealing with short-lived psychotic episodes, and they also do not feel that these patients 
should be referred to the deputy services who should take care of these patients. The pragmatic failure of the 
CHR-P paradigm in detecting people at risk of developing psychosis has recently been reported by our 
group7,13,27. Notably, this failure has been observed in the context of well-established CHR-P services with 
extensive outreach to promote referrals from NHS clinicians. Further investing in outreach campaigns in the 
local Mental Health Trust to persuade clinicians to refer these patients to the deputy services is unlikely to be 
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successful, because these strategies are already ongoing and demonstrate high inefficiency7. Rather, a recent 
automatized calculator has been developed to screen at scale individuals accessing mental health Trusts and 
detect those who may be at high risk of developing persistent psychotic disorders13. This calculator is 
particularly useful to detect ATPDs patients. This clinical risk prediction model employs data collected as part 
of clinical routine in electronic health registries such as the one that has been used to perform the current study. 
Leveraging on these data, it allows an individualized prediction of outcomes in ATPDs patients, facilitating 
the treatment or follow-up offered to these patients. The validity of the calculator has recently been replicated 
in another mental health trust and a pilot study is currently testing the feasibility of using it in the real world 
mental health care28.  The second step for improving the care of these patients would be to reconciliate the 
different operationalizations employed to identify these patients29, and the inefficient split between EIS and 
CHR-P services, which is constructed around arbitrary thresholds such as more or less than 7-days duration of 
the initial episode. The third step would be to refine interventional research for these patients, and to update 
treatment guidelines accordingly.  
 
The present study has some limitations.  
Diagnoses recorded in CRIS as part of clinical routine are excellent in terms of ecological validity, but they 
are not validated with research-based criteria. However, data recorded in electronic health registers has 
previously been shown to have good reliability for psychotic disorders30,31. Further, in previous studies we 
have demonstrated that the use of these diagnoses is empirically valid, even outside the local mental health 
trust28. 
Patients were not systematically assessed during follow-up. We relied on clinical routine data, which is 
influenced by patient and service-related factors. However, we recently validated our approach, by showing 
that psychotic outcomes that were estimated through our electronic case register were consistent with those 
reported by other sites12.  
Finally, we did not report data on future transition to persistent psychotic disorders. It is possible to hypothesize 
that the long-term outcomes reported in this manuscript overlaps, at least partially, with transition to a 
persistent psychotic disorder.  
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5. Conclusions 
In real-word clinical practice, the majority of ATPDs are not detected or treated by EIS or CHR-P services, 
receive heterogeneous treatments and only short-term clinical follow-up. ATPDs have a high risk of 
developing severe clinical outcomes beyond persistent psychotic disorders. These patients have unmet clinical 
needs that are not targeted by current mental health services. 
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Table 1. Sociodemographic and clinical characteristics of patients with a first index diagnosis of 
ICD-10 Acute and Transient Psychotic Disorder (ATPD). 
 
Sociodemographic characteristics     
  N Mean SD 
Age   2559 33.58 13.86 
  N Count % 
Gender  2561   
 Males  1333 52.05 
 Females  1228 47.95 
Self- assigned ethnicity  2481   
 Any white  896 36.11 
 Any black  948 38.21 
 Any asian  195 7.86 
 Mixed  57 2.30 
 Others  385 15.52 
Clinical characteristics ICD-10 code N Count % 
ATPD subtype  2561   
Acute Polymorphic Psychotic Disorder (APPD) F23.0  116 4.53 
APPD with symptoms of Schizophrenia F23.1  131 5.12 
Acute Schizophrenia-like Psychotic Disorder F23.2  366 14.29 
Other Acute Predominantly Delusional Psychotic 
Disorder 
F23.3  199 4.65 
Other/Unspecified Acute Transient Psychotic Disorder F23.8 or 
F23.9 
 1641 64.08 
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Figure 1. Pathways to care in patients with Acute and Transient Psychotic Disorders 
(ATPDs). Percentage of individuals with ATPDs assigned to the different SLaM services for 
assessment (figure 1a) and percentage of individuals with ATPDs assigned to the different SLaM 
services for diagnosis and treatment (figure 1b). No patients were detected/treated by CHR-P 
services. 
 
Figure 2. Treatments received by ATPDs. Histogram chart reporting the relative frequencies of 
treatments received by patients with Acute and Transient Psychotic Disorders (ATPDs) at different 
time points.  
 
Figure 3. Long-term outcomes in ATPDs. Histogram chart reporting the percentage of ATPDs 
patients that received at least one mental health hospitalization and one compulsory hospital admission 
(under the Mental Health Act) over 8 years of follow-up. 
 
